A Randomized Phase 2 Trial of Induction Chemotherapy and Concurrent Chrono-chemotherapy with Radiation Therapy in Locally Advanced Nasopharyngeal Carcinoma
P. Zhang,F. Jin,Z. Li,W. Wu,Y. Li,J. Long
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1423
2017-01-01
Abstract:To evaluate the effectiveness and safety of induction chemotherapy plus concurrent chrono-chemotherapy followed by intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma. From December 2013 to November 2014,148 patients with stage III-IVb nasopharyngeal carcinoma were randomized deviding into study group and control group in Guizhou Cancer Hospital. Both study and control group received 2 cycles induction chemotherapy(Docetaxel 75mg/m2,infusion,d1. Cisplatin 75mg/ m2,infusion,d1. 5-fluorouracil 750mg/ m2/d,continuous intravenous pumping,d1-5(120 hours),21days/cycle,for two cycles.),and 3 cycles of concurrent chrono-chemotherapy with IMRT were gone through in the study group(cisplatin,100mg/m2,10:00-22:00,continuous intravenous pumping,d1,21days/cycle,for three cycles) while the control group received 3 cycles of conventional chemotherapy with IMRT. Dose given on Concurrent radiotherapy with intensity modulated radiotherapy: T1-2:GTVnx DT=69.96Gy/33f,T3-4:GTVnx DT=73.92Gy/33f,PTVnx DT=69.96Gy/33f,PGTVnd DT=69.96Gy/33f,PGTVrpn DT=69.96Gy/33f,PTV1 DT=60.06Gy/33f,PTV2 DT=50.96Gy/28f. The two groups were compared in terms of recent curative effect, adverse effects and overall survival. 136 patients achieved either CR or PR, resulting in a RR of 95.8% for the entire patient cohort. Of which 67(97.1%) patients in group study and 69(95.7%) patients in group control achieved RR. With a median follow-up of 20 months, To compare with the control group ,the study group have a better outcomes in recent adverse effects and immune functions. During the phase of concurrent chemoradiotherapy, the incidence of nausea, vomiting and oral mucositis in two groups was 66.7%:79.5%(p<0.05), 47.9%:71.2%(p<0.05), 73.9%:87.7%(p<0.05) respectively. 126 patients were sequentially tested by the hematological examination of T-lymphocyte counting after concurrent treatment, however, 16 patients failed to evaluate the immune functions because they refused to receive such examination. The ratio of CD4+/CD8+ in study group were significantly higher than control group(t=3.27, p˂0.05). The 2-year overall survival in study group was 92.8%, compare to 93.2% for control group. And no significant differences were found in 2-year OS(p=0.95), PFS(p=0.40)and DMFS(p=0.16) between the two groups. Induction chemotherapy plus concurrent chrono-chemotherapy integrated with intensity modulated radiotherapy may become a proper treatment for its remaining curative effect and promising survival while reducing adverse effects and improving immune function at the same time, and providing a favorable foundation for the phase III trail prospectively. However, it should be noted that the number of cases in this study is limited, more multi-institutional studies are needed. Furthermore, confirming its long-term outcomes awaits further follow-up.